General non-hematologic dose modifications for poly (ADP-ribose) polymerase inhibitor (PARPi) treatment
| Severity | Management |
| Grade 1 | Continue treatment Consider dose interruptions or reductions if considered clinically intolerable by the patient, despite adequate symptom management |
| Grade 2 | Continue treatment Consider dose interruptions or reductions if it does not improve with symptom management, or if considered clinically intolerable by the patient |
| Grade≥3 where prophylaxis is not feasible or AE persists despite treatment | Withhold for a maximum of 28 days or until resolution of adverse reaction; then, consider dose reduction. |
| Grade ≥3 lasting >28 days on the lowest dose-level | If AE persists despite adequate management, permanently discontinue medication |
AE, adverse event.